Overview

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in disease-related health status, COPD symptoms and COPD exacerbations.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Bromides